52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Thermo Fisher Scientific Expect Full Year 2020 Organic Revenue Growth To Be In The Range Of 13% To 16%
FDA Approves First NGS-Based Companion Diagnostic For Ret Fusion-Positive Non-Small Cell Lung Cancer
Thermo Fisher Scientific Says Has Terminated Acquisition Agreement With Qiagen
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.
Medical Equipment & Supplies
168 3rd Ave
Marc N. Casper
Chairman of the Board, President, Chief Executive Officer
Chief Financial Officer, Senior Vice President
Mark P. Stevenson
Chief Operating Officer, Executive Vice President
Executive Vice President
Michael A. Boxer
Senior Vice President, General Counsel
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture the drug developer's experimental coronavirus vaccine, as it looks to boost the supply ahead of large trials this month.
Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture its experimental coronavirus vaccine to boost the supply of the vaccine.
Qiagen <QIA.DE> said its non-executive Chairman Hakan Bjoerklund had resigned with immediate effect after the genetic testing company's shareholders rejected an improved takeover offer from Thermo Fisher <TMO.N>.
Thermo Fisher <TMO.N> has walked away from its takeover deal with Qiagen <QIA.DE> after the German genetic testing specialist's earnings were boosted by coronavirus diagnostics, leaving its shareholders reluctant to cash out.
Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met. Thermo Fisher's revised offer had valued Qiagen at 11.3 billion euros ($13.38...
Thermo Fisher Scientific <TMO.N> said that the results of its sweetened takeover offer for German genetic testing company Qiagen <QIA.DE> would be unveiled on Thursday or soon thereafter.
Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen <QIA.DE>, days after Thermo Fisher Scientific <TMO.N> said its offer to buy the German genetic test maker expires soon.
Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen , days after Thermo Fisher Scientific said its offer to buy the German genetic test maker expires soon.
Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen <QIA.DE> to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.
Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen <QIA.DE>, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.
Thermo Fisher Scientific raised its bid for Qiagen by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.
Hedge fund Davidson Kempner said on Wednesday Thermo Fisher Scientific's <TMO.N> offer to buy German genetic test maker Qiagen <QIA.DE> was "wholly inadequate" and that it would not be tendering its shares into the deal at the current price.
Hedge fund Davidson Kempner said on Wednesday Thermo Fisher's acquisition offer for German genetic test maker Qiagen was "wholly inadequate" and that it would not tenderings its share into the deal at the current offer.
* DAVIDSON KEMPNER EUROPEAN PARTNERS SENDS LETTER TO QIAGEN NV
Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's <TMO.N> current offer to acquire German genetic test maker Qiagen NV <QIA.DE> to be "inadequate" and would not tender its shares into the offer.
Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's current offer to acquire German genetic test maker Qiagen NV to be "inadequate" and will not tender its shares into the offer.
* SETS QUARTERLY CASH DIVIDEND OF $0.22PER SHARE Source text for Eikon: Further company coverage:
* THERMO FISHER SCIENTIFIC SIGNS COMPANION DIAGNOSTIC AGREEMENT WITH CHUGAI PHARMACEUTICAL
* THERMO FISHER SCIENTIFIC - ESTIMATES BOTH REPORTED, ORGANIC REVENUE GROWTH WILL BE ABOUT 10% FOR Q2
The coronavirus pandemic has boosted Qiagen's <QIA.DE> prospects and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.